van Leeuwen, Leanne P. M.
Grobben, Marloes
GeurtsvanKessel, Corine H.
Ellerbroek, Pauline M.
de Bree, Godelieve J.
Potjewijd, Judith
Rutgers, Abraham
Jolink, Hetty
van de Veerdonk, Frank L.
van Gils, Marit J.
de Vries, Rory D.
Dalm, Virgil A. S. H. http://orcid.org/0000-0001-5945-4435
van Gorp, Eric C. M.
de Wilt, Faye
Bogers, Susanne
Gommers, Lennert
Geers, Daryl
van der Ent, Marianne W.
van Hagen, P. Martin
van Haga, Jelle W.
Lemkes, Bregtje A.
van der Veen, Annelou
Sanders, Rogier W.
van der Straten, Karlijn
Burger, Judith A.
van Rijswijk, Jacqueline
Tejjani, Khadija
Bouhuijs, Joey H.
de Leeuw, Karina
van de Ven, Annick A. J. M.
de Kruijf-Bazen, S. F. J.
van Paassen, Pieter
Wieten, Lotte
Verbeek-Menken, Petra H.
van Wengen, Annelies
Bruns, Anke H. W.
Leavis, Helen L.
Nierkens, Stefan
,
Funding for this research was provided by:
ZonMW (10430072010006)
Article History
Received: 3 January 2023
Accepted: 8 May 2023
First Online: 26 May 2023
Declarations
:
: The Vaccination Against COvid in Primary Immune Deficiencies (VACOPID) adheres to the principles of the Declaration of Helsinki and was approved by the Dutch Central Committee on Research Involving Human Subjects (CCMO, NL7647.078.21, EudraCT number 2021–000515-24), the Medical Research Ethics Committee from Erasmus University Medical Center (MEC-2021–0050) and the local review boards of all other participating centers. EudraCT Number: 2021–000515-24.
: Written informed consent was obtained from all individual participants included in the study.
: All authors agreed to this publication.
: JP received a grant from GlaxoSmithKline for an improvement of clinical care project and received support from Prothva Biosolutions for attending meetings and cover of travel expenses. JP participates in an Advisory Board for Janssen. FV received a grant from ZonMW for a study on lanadelumab in COVID-19, and consulting fees from GSK made to his department. VD received consulting fees from GlaxoSmithKline, Pharming NV for Advisory board meetings and honoraria for lectures from Takeda Pharmaceutical Company, Kedrion, AstraZeneca. All other authors declare no competing interests.